Invivyd’s Covid vaccine alternative advances but may face an FDA hurdle
🤖 AI-generated content — The title and summary were produced automatically by artificial intelligence, without human editorial review.
Small biotechnology company Invivyd is developing an injectable, low-dose monoclonal antibody as an alternative way to protect people against Covid. The program has received a boost, though it may still encounter an FDA hurdle.
Continue in the app — vote & join in ➔Source: STAT News · via ahirlevel.hu